Clinical Trials Browser

Completed × OTHER × duvelisib × Clear all

NCT02783625 2026-04-24

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Phase 1 Completed

Lymphoma, Lymphoma, T-Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase 1 Completed

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05057247 2025-10-31

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Phase 2 Completed

26 enrolled 23 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04890236 2025-01-20

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Phase EARLY_PHASE1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms